MyMedR

Displaying all 5 publications

Abstract:

Sort:

Fulltext Anti-diabetic potential of Catharanthus roseus Linn. and its effect on the glucose transport gene (GLUT-2 and GLUT-4) in streptozotocin induced diabetic wistar rats

Al-Shaqha WM, Khan M, Salam N, Azzi A, Chaudhary AA

BMC Complement Altern Med, 2015;15:379.
PMID: 26490765 DOI: 10.1186/s12906-015-0899-6

Catharanthus roseus is an important Ayurvedic medication in traditional medicine. It is potentially used in countries like India, South Africa, China and Malaysia for the healing of diabetes mellitus. Although, the molecular mechanisms behind this effect are yet to be exclusively explored. Due to the great antidiabetic and hyperlipidemic potential of c. roseus, we hypothesized that the insulin mimetic effect of ethanolic extract of c. roseus might add to glucose uptake through improvement in the expression of genes of the glucose transporter (GLUT) family messenger RNA (mRNA) in liver.
Nanostructured material-based optical and electrochemical detection of amoxicillin antibiotic

Imran M, Ahmed S, Abdullah AZ, Hakami J, Chaudhary AA, Rudayni HA, et al.

Luminescence, 2023 Jul;38(7):1064-1086.
PMID: 36378274 DOI: 10.1002/bio.4408

The penicillin derivative amoxicillin (AMX) plays an important role in treating various types of infections caused by bacteria. However, excessive use of AMX may have negative health effects. Therefore, it is of utmost importance to detect and quantify the AMX in pharmaceutical drugs, biological fluids, and environmental samples with high sensitivity. Therefore, this review article provides valuable and up-to-date information on nanostructured material-based optical and electrochemical sensors to detect AMX in various biological and chemical samples. The role of using different nanostructured materials on the performance of important optical sensors such as colorimetric sensors, fluorescence sensors, surface-enhanced Raman scattering sensors, chemiluminescence/electroluminescence sensors, optical immunosensors, optical fibre-based sensors, and several important electrochemical sensors based on different electrode types have been discussed. Moreover, nanocomposites, polymer, and MXenes-based electrochemical sensors have also been discussed, in which such materials are being used to further enhance the sensitivity of these sensors. Furthermore, nanocomposite-based photo-electrochemical sensors and the market availability of biosensors including AMX have also been discussed briefly. Finally, the conclusion, challenges, and future perspectives of the above-mentioned sensing techniques for AMX detection are presented.
Unraveling cancer progression pathways and phytochemical therapeutic strategies for its management

Sharma V, Chaudhary AA, Bawari S, Gupta S, Mishra R, Khan SU, et al.

Front Pharmacol, 2024;15:1414790.
PMID: 39246660 DOI: 10.3389/fphar.2024.1414790

Cancer prevention is currently envisioned as a molecular-based approach to prevent carcinogenesis in pre-cancerous stages, i.e., dysplasia and carcinoma in situ. Cancer is the second-leading cause of mortality worldwide, and a more than 61% increase is expected by 2040. A detailed exploration of cancer progression pathways, including the NF-kβ signaling pathway, Wnt-B catenin signaling pathway, JAK-STAT pathway, TNF-α-mediated pathway, MAPK/mTOR pathway, and apoptotic and angiogenic pathways and effector molecules involved in cancer development, has been discussed in the manuscript. Critical evaluation of these effector molecules through molecular approaches using phytomolecules can intersect cancer formation and its metastasis. Manipulation of effector molecules like NF-kβ, SOCS, β-catenin, BAX, BAK, VEGF, STAT, Bcl2, p53, caspases, and CDKs has played an important role in inhibiting tumor growth and its spread. Plant-derived secondary metabolites obtained from natural sources have been extensively studied for their cancer-preventing potential in the last few decades. Eugenol, anethole, capsaicin, sanguinarine, EGCG, 6-gingerol, and resveratrol are some examples of such interesting lead molecules and are mentioned in the manuscript. This work is an attempt to put forward a comprehensive approach to understanding cancer progression pathways and their management using effector herbal molecules. The role of different plant metabolites and their chronic toxicity profiling in modulating cancer development pathways has also been highlighted.
Global, Regional, and National Burden of Bone Cancers, 1990 to 2023, With Forecasts to 2050: A Systematic Analysis for the Global Burden of Disease Study 2023

GBD 2023 Bone Cancer Collaborators, Monsereenusorn C, Bisignano C, May ML, Pritchett N, Kocarnik JM, et al.

JAMA Oncol, 2026 Oct 29.
PMID: 42955027 DOI: 10.1001/jamaoncol.2026.4274

IMPORTANCE: Primary bone cancers include multiple histologic types, with survival differing by age and location. Results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 were analyzed to support policies and initiatives worldwide.
OBJECTIVE: To estimate the global burden of bone cancer from 1990 to 2023 and forecast future trends to 2050.
DESIGN, SETTING, AND PARTICIPANTS: This systematic analysis estimated bone cancer incidence, mortality, and disability-adjusted life-years (DALYs) in 204 countries and territories grouped by GBD super-regions and World Bank income groups from 1990 to 2023, with forecasts through 2050. Individuals of all ages with bone cancers included in the GBD 2023 study were included in analyses. Data were analyzed from June 2023 to July 2025.
MAIN OUTCOMES AND MEASURES: The GBD 2023 study used standardized estimation methods to describe bone cancer incidence, mortality, and DALYs in 2023, as well as trends over the past 3 decades and forecasts through 2050. All estimates are presented with 95% uncertainty intervals (UIs), and age-standardized rates (ASRs) were calculated using GBD-specific age weights.
RESULTS: In 2023, there were 111 000 (95% UI, 81 300-164 000) malignant bone cancer cases, 76 600 (95% UI, 60 700-96 300) deaths, and 3.02 million (95% UI, 2.29 million-3.96 million) DALYs globally. A bimodal age distribution was noted in both incidence (peaking at ages 10 to 14 years and 65 to 69 years) and mortality (peaking at ages 15 to 19 years and 65 to 69 years). The highest ASRs for incidence were in Southeast Asia, East Asia, and Oceania (1.6 per 100 000; 95% UI, 1.1-2.4), while Sub-Saharan Africa had the highest ASRs for DALYs (51.0 per 100 000; 95% UI, 27.7-79.7). By World Bank income group, upper-middle-income countries had the highest ASRs for incidence, whereas low-income countries exhibited the highest ASRs for both mortality and DALYs. Globally, incident cases, deaths, and DALYs increased from 1990 to 2023, while global mortality and DALY ASRs were relatively stable; high-income countries experienced a decline in mortality and DALY ASRs. Forecasts suggest a potential increase in global cases and deaths by 2050.
CONCLUSIONS AND RELEVANCE: In this systematic analysis, the burden of bone cancer varied by age, geography, and time, underscoring global disparities. These findings provide valuable insights to inform health system planning and resource allocation tailored to different settings.
Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023

GBD 2023 LDL Cholesterol Collaborators, Razo C, DeCleene NK, Johnson CO, Stark BA, LeGrand K, et al.

JAMA, 2026 Aug 25;336(8):673-698.
PMID: 42525403 DOI: 10.1001/jama.2026.8628

IMPORTANCE: Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C-related burden is critical for guiding prevention and treatment strategies.
OBJECTIVES: To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends.
DESIGN, SETTING, AND POPULATION: This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals.
EXPOSURE: Population-level LDL-C concentrations.
MAIN OUTCOMES AND MEASURES: Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C-attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals.
RESULTS: In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C-attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings.
CONCLUSIONS AND RELEVANCE: Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.